A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793494170 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study

Yearbook of Urology ◽

10.1016/j.yuro.2011.06.011 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

A.S. Kibel

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Re: Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study

The Journal of Urology ◽

10.1016/j.juro.2011.08.108 ◽

2011 ◽

Vol 186 (6) ◽

pp. 2254-2255 ◽

Cited By ~ 1

Author(s):

Patrick C. Walsh

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Faculty Opinions recommendation of Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740905744.793589416 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

The Lancet ◽

10.1016/s0140-6736(10)62344-6 ◽

2011 ◽

Vol 377 (9768) ◽

pp. 813-822 ◽

Cited By ~ 1203

Author(s):

Karim Fizazi ◽

Michael Carducci ◽

Matthew Smith ◽

Ronaldo Damião ◽

Janet Brown ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30860-x ◽

2019 ◽

Vol 20 (3) ◽

pp. 408-419 ◽

Cited By ~ 89

Author(s):

Matthew Smith ◽

Chris Parker ◽

Fred Saad ◽

Kurt Miller ◽

Bertrand Tombal ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study

International Journal of Urology ◽

10.1111/iju.13051 ◽

2016 ◽

Vol 23 (5) ◽

pp. 404-411 ◽

Cited By ~ 11

Author(s):

Yinghao Sun ◽

Qing Zou ◽

Zhongquan Sun ◽

Changling Li ◽

Chuanjun Du ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Bridging Study

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793514277 ◽

2016 ◽

Author(s):

Badrinath Konety

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽